Nicotine polacrilex dose effects

serum nicotine levels and sensory characteristics

Scott Leischow, D. P L Sachs, M. D. Hansen, A. G. Bostrom

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This study evaluated serum nicotine and sensory differences of five different doses of nicotine polacrilex (0.0, 0.5, 1.0, 2.0 and 4.0 mg nicotine), three of which have been used as placebo doses in clinical trials (0.0, 0.5, and 1.0 mg) and two of which are currently available as pharmacologic treatments for smoking cessation (2.0 or 4.0 mg nicotine). Twenty-one smokers received, on different days and in random order, five pieces of each of the five doses of polacrilex. The objective of the study was to evaluate whether consistent serum nicotine and sensory differences would be observed between the doses. After 5 h use, the 0.0, 0.5, 1.0, 2.0, and 4.0 mg doses produced the following results: (1) there was a linear trend across the placebo doses of nicotine polacrilex in serum nicotine and nicotine flavor, although pairwise dose comparisons were not significant, (2) the 0.0 and 0.5 mg placebo doses resulted in serum nicotine and sensory ratings that were significantly different from the 2.0 mg dose, and even more so from the 4.0 mg dose, (3) the 1.0 mg dose was not different from the 2.0 mg dose on serum nicotine level and several sensory characteristics, though it was different from the 4.0 mg dose on both, and (4) the 4.0 mg dose resulted in significantly higher serum nicotine and usually higher sensory ratings than the 2.0 mg dose. Since the 0.0 mg placebo achieves sensory effects that are comparable to the nicotine-containing placebo doses, it is recommended over the 0.5 and 1.0 mg doses as the nicotine polacrilex placebo of choice in most clinical trials.

Original languageEnglish (US)
Pages (from-to)125-129
Number of pages5
JournalPsychopharmacology
Volume117
Issue number2
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Tobacco Use Cessation Products
Nicotine
Serum
Placebos
Clinical Trials
Smoking Cessation

Keywords

  • Nicotine
  • Nicotine polacrilex
  • Sensory
  • Smoking Placebo

ASJC Scopus subject areas

  • Pharmacology

Cite this

Nicotine polacrilex dose effects : serum nicotine levels and sensory characteristics. / Leischow, Scott; Sachs, D. P L; Hansen, M. D.; Bostrom, A. G.

In: Psychopharmacology, Vol. 117, No. 2, 01.01.1995, p. 125-129.

Research output: Contribution to journalArticle

Leischow, Scott ; Sachs, D. P L ; Hansen, M. D. ; Bostrom, A. G. / Nicotine polacrilex dose effects : serum nicotine levels and sensory characteristics. In: Psychopharmacology. 1995 ; Vol. 117, No. 2. pp. 125-129.
@article{0f7ed63688f64f5eb4cf37498808b230,
title = "Nicotine polacrilex dose effects: serum nicotine levels and sensory characteristics",
abstract = "This study evaluated serum nicotine and sensory differences of five different doses of nicotine polacrilex (0.0, 0.5, 1.0, 2.0 and 4.0 mg nicotine), three of which have been used as placebo doses in clinical trials (0.0, 0.5, and 1.0 mg) and two of which are currently available as pharmacologic treatments for smoking cessation (2.0 or 4.0 mg nicotine). Twenty-one smokers received, on different days and in random order, five pieces of each of the five doses of polacrilex. The objective of the study was to evaluate whether consistent serum nicotine and sensory differences would be observed between the doses. After 5 h use, the 0.0, 0.5, 1.0, 2.0, and 4.0 mg doses produced the following results: (1) there was a linear trend across the placebo doses of nicotine polacrilex in serum nicotine and nicotine flavor, although pairwise dose comparisons were not significant, (2) the 0.0 and 0.5 mg placebo doses resulted in serum nicotine and sensory ratings that were significantly different from the 2.0 mg dose, and even more so from the 4.0 mg dose, (3) the 1.0 mg dose was not different from the 2.0 mg dose on serum nicotine level and several sensory characteristics, though it was different from the 4.0 mg dose on both, and (4) the 4.0 mg dose resulted in significantly higher serum nicotine and usually higher sensory ratings than the 2.0 mg dose. Since the 0.0 mg placebo achieves sensory effects that are comparable to the nicotine-containing placebo doses, it is recommended over the 0.5 and 1.0 mg doses as the nicotine polacrilex placebo of choice in most clinical trials.",
keywords = "Nicotine, Nicotine polacrilex, Sensory, Smoking Placebo",
author = "Scott Leischow and Sachs, {D. P L} and Hansen, {M. D.} and Bostrom, {A. G.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1007/BF02245177",
language = "English (US)",
volume = "117",
pages = "125--129",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Nicotine polacrilex dose effects

T2 - serum nicotine levels and sensory characteristics

AU - Leischow, Scott

AU - Sachs, D. P L

AU - Hansen, M. D.

AU - Bostrom, A. G.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - This study evaluated serum nicotine and sensory differences of five different doses of nicotine polacrilex (0.0, 0.5, 1.0, 2.0 and 4.0 mg nicotine), three of which have been used as placebo doses in clinical trials (0.0, 0.5, and 1.0 mg) and two of which are currently available as pharmacologic treatments for smoking cessation (2.0 or 4.0 mg nicotine). Twenty-one smokers received, on different days and in random order, five pieces of each of the five doses of polacrilex. The objective of the study was to evaluate whether consistent serum nicotine and sensory differences would be observed between the doses. After 5 h use, the 0.0, 0.5, 1.0, 2.0, and 4.0 mg doses produced the following results: (1) there was a linear trend across the placebo doses of nicotine polacrilex in serum nicotine and nicotine flavor, although pairwise dose comparisons were not significant, (2) the 0.0 and 0.5 mg placebo doses resulted in serum nicotine and sensory ratings that were significantly different from the 2.0 mg dose, and even more so from the 4.0 mg dose, (3) the 1.0 mg dose was not different from the 2.0 mg dose on serum nicotine level and several sensory characteristics, though it was different from the 4.0 mg dose on both, and (4) the 4.0 mg dose resulted in significantly higher serum nicotine and usually higher sensory ratings than the 2.0 mg dose. Since the 0.0 mg placebo achieves sensory effects that are comparable to the nicotine-containing placebo doses, it is recommended over the 0.5 and 1.0 mg doses as the nicotine polacrilex placebo of choice in most clinical trials.

AB - This study evaluated serum nicotine and sensory differences of five different doses of nicotine polacrilex (0.0, 0.5, 1.0, 2.0 and 4.0 mg nicotine), three of which have been used as placebo doses in clinical trials (0.0, 0.5, and 1.0 mg) and two of which are currently available as pharmacologic treatments for smoking cessation (2.0 or 4.0 mg nicotine). Twenty-one smokers received, on different days and in random order, five pieces of each of the five doses of polacrilex. The objective of the study was to evaluate whether consistent serum nicotine and sensory differences would be observed between the doses. After 5 h use, the 0.0, 0.5, 1.0, 2.0, and 4.0 mg doses produced the following results: (1) there was a linear trend across the placebo doses of nicotine polacrilex in serum nicotine and nicotine flavor, although pairwise dose comparisons were not significant, (2) the 0.0 and 0.5 mg placebo doses resulted in serum nicotine and sensory ratings that were significantly different from the 2.0 mg dose, and even more so from the 4.0 mg dose, (3) the 1.0 mg dose was not different from the 2.0 mg dose on serum nicotine level and several sensory characteristics, though it was different from the 4.0 mg dose on both, and (4) the 4.0 mg dose resulted in significantly higher serum nicotine and usually higher sensory ratings than the 2.0 mg dose. Since the 0.0 mg placebo achieves sensory effects that are comparable to the nicotine-containing placebo doses, it is recommended over the 0.5 and 1.0 mg doses as the nicotine polacrilex placebo of choice in most clinical trials.

KW - Nicotine

KW - Nicotine polacrilex

KW - Sensory

KW - Smoking Placebo

UR - http://www.scopus.com/inward/record.url?scp=0028797384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028797384&partnerID=8YFLogxK

U2 - 10.1007/BF02245177

DO - 10.1007/BF02245177

M3 - Article

VL - 117

SP - 125

EP - 129

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2

ER -